Get to know our clinical trials
Clinical trial of iberdomide, daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma
THE OBJECTIVE OF THIS STUDY IS TO TEST THE EFFICACY OF AN INVESTIGATIONAL NEW DRUG, IBERDOMIDE (CC-220), TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHEN USED IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE.
Technical Summary
- PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY TO COMPARE IBERDOMIDE, DARATUMUMAB AND DEXAMETHASONE (IBERDD) WITH DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MMRR). IMMUNOTHERAPY
- Code EudraCT: 2020-000431-49
- Protocol number: CC-220-MM-002
- Promoter: Celgene Corporation
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.